Vivus, Inc. announced that Qsymia (phentermine and topiramate extended-release) capsules are now available. Qsymia (formerly known as Qnexa) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of >30 (obese), or >27 (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia).
Qsymia is the first once-daily combination treatment for obesity management. Qsymia was approved with a Risk Evaluation and Mitigation Strategy (REMS) program, which includes a Medication Guide, healthcare provider training, patient brochure, and other education tools.
Qsymia (Schedule C-IV) is available in 3.75mg/23mg in a 14- and 30-count bottles, and 7.5mg/46mg, 11.25mg/69mg, and 15mg/92mg dosage strength capsules in 30-count bottles. Qsymia is available only through certified mail order pharmacies that are part of the Qsymia Home Delivery Network.
For more information call (650) 934-5200 or visit www.Qsymia.com.